Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) EPS (Basic) (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed EPS (Basic) for 6 consecutive years, with -$0.3 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 21.05% to -$0.3 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.65, a 4.43% decrease, with the full-year FY2025 number at -$1.59, up 3.64% from a year prior.
  • EPS (Basic) was -$0.3 for Q3 2025 at Caribou Biosciences, up from -$0.58 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.09 in Q4 2021 to a low of -$1.39 in Q1 2021.
  • A 5-year average of -$0.48 and a median of -$0.44 in 2022 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): skyrocketed 105.37% in 2021, then tumbled 600.0% in 2022.
  • Caribou Biosciences' EPS (Basic) stood at $0.09 in 2021, then crashed by 600.0% to -$0.45 in 2022, then grew by 28.89% to -$0.32 in 2023, then fell by 21.88% to -$0.39 in 2024, then rose by 23.08% to -$0.3 in 2025.
  • Per Business Quant, the three most recent readings for CRBU's EPS (Basic) are -$0.3 (Q3 2025), -$0.58 (Q2 2025), and -$0.39 (Q4 2024).